メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
生物統計学
医学部
医学部基礎教室
概要
フィンガープリント
ネットワーク
プロファイル
(1)
研究成果
(162)
フィンガープリント
生物統計学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Cohort Analysis
59%
Randomized Controlled Trial
58%
Patient with Type 2 Diabetes
50%
Congenital Diaphragm Hernia
47%
Tofogliflozin
43%
COVID-19
40%
Maturity Onset Diabetes of the Young
36%
Cardiovascular Disease
36%
Quality of Life
35%
Disease
34%
Hazard Ratio
30%
Hemoglobin A1c
29%
Brain Metastasis
28%
Anterior Chamber of Eyeball
28%
Aortic Dissection
28%
Mycobacterium Avium Complex
28%
Silo-Filler's Disease
28%
Adverse Event
24%
Group Therapy
23%
Observational Study
22%
Endovascular Aneurysm Repair
22%
Atherosclerosis
22%
Symptom
22%
Diabetes Mellitus
22%
Retrospective Cohort Study
22%
Hemodialysis
22%
Telemedicine
22%
Prospective Study
20%
Odds Ratio
20%
Disease Exacerbation
20%
Overall Survival
19%
Cross Sectional Study
19%
Diseases
19%
Clinical Trial
19%
Dry Eye
19%
Tear Film
19%
Graft Versus Host Reaction
19%
Small Cell Lung Cancer
19%
Stereotactic Radiosurgery
19%
Post-Hoc Analysis
19%
Iliac Artery
19%
COVID-19 Vaccination
19%
Sitagliptin
19%
Prognostic Assessment
19%
Surgical Infection
19%
Controlled Clinical Trial
19%
Olanexidine
19%
Coronavirinae
19%
Diagnosis
17%
Eye Disease
17%
Diabetes
16%
Limb
16%
Infection
16%
Optical Coherence Tomography
15%
Cardiovascular System
14%
Prevalence
14%
Sodium Glucose Cotransporter 2 Inhibitor
14%
Artificial Respiration
14%
Arm
14%
Intima-Media Thickness
14%
Elderly Patient
14%
Advanced Cancer
14%
Combination Therapy
14%
Lung Cancer
13%
Drug Therapy
13%
Body Mass Index
13%
Clinical Feature
12%
Obsessive Compulsive Disorder
12%
Systolic Blood Pressure
12%
Glycon
12%
Recurrence Free Survival
11%
Sequela
11%
Asthma
11%
Dyspnea
11%
Health Care Cost
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Vasculotropin
11%
Chronic Kidney Disease
11%
Preventive Medicine
11%
Glomerular Filtration Rate
11%
Scoring System
11%
Postoperative Complication
11%
Politef
11%
Kidney Function
10%
Blood Pressure
10%
Chronic Obstructive Pulmonary Disease
10%
Glycemic Control
10%
Heart Failure
10%
Pediatrics
10%
Extracorporeal Membrane Oxygenation
10%
Oxygen Therapy
10%
Mortality Rate
10%
Chronic Inflammatory Demyelinating Polyneuropathy
9%
Radiosurgery
9%
Blood Clotting
9%
Thymoma
9%
Short Form 36
9%
Endocrine Disease
9%
Ferritin
9%
Chest Radiograph
9%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Non Insulin Dependent Diabetes Mellitus
60%
Disease
53%
Tofogliflozin
53%
Coronavirinae
47%
Chronic Obstructive Lung Disease
39%
Cardiovascular Disease
37%
Disease Exacerbation
36%
Clinical Trial
31%
Brain Metastasis
28%
Hemodialysis
28%
Congenital Diaphragm Hernia
28%
Hemoglobin A1c
28%
Symptom
28%
Overall Survival
25%
Atherosclerosis
23%
Prospective Cohort Study
22%
Adverse Event
21%
Diabetes Mellitus
20%
Diseases
19%
Aortic Dissection
19%
Lung Disease
19%
Chronic Kidney Failure
19%
Syndrome
19%
Methotrexate
19%
Rheumatoid Arthritis
19%
Chronic Thromboembolic Pulmonary Hypertension
19%
Clinical Feature
18%
SARS Coronavirus
18%
Prevalence
17%
Infection
15%
Sodium Glucose Cotransporter 2 Inhibitor
15%
Vasculotropin
14%
Dexamethasone
14%
Placebo
14%
Normal Human
14%
Chemotherapy
14%
Dyspnea
13%
Randomized Controlled Trial
13%
All Cause Mortality
13%
Disease Activity
12%
Adalimumab
12%
Metformin
12%
Recurrence Free Survival
11%
Combination Therapy
11%
Cause of Death
11%
Polyneuropathy
11%
Heart Failure
11%
Prospective Study
10%
Tacrolimus
10%
Progression Free Survival
10%
Biological Marker
10%
Cardiovascular Risk
9%
Small Cell Lung Cancer
9%
Metastatic Colorectal Cancer
9%
Endocrine Disease
9%
Graft Versus Host Reaction
9%
Topiroxostat
9%
SLCO1B1
9%
Sitagliptin
9%
Ipragliflozin
9%
Mycobacterium Avium Complex
9%
Cross-Sectional Study
9%
Baricitinib
9%
Mucin 1
9%
Thalidomide
9%
Heart Failure with Reduced Ejection Fraction
9%
Drug Discovery
9%
Ropinirole
9%
Myasthenia gravis
9%
Thymoma
9%
Cholinergic Receptor Antibody
9%
M Protein
9%
Noninferiority Trial
9%
Lenalidomide
9%
Uric Acid
9%
Pharmacotherapy
9%
Riociguat
9%
Denosumab
9%
Comparison Trial
9%
Vaccination Policy
9%
Hypocalcaemia
9%
Adrenal Cortex Insufficiency
9%
Nonischemic Cardiomyopathy
9%
Adrenal Insufficiency
9%
Neuropathy
9%
Myelin Associated Glycoprotein
9%
Conjunctiva Disease
9%
Kidney Cancer
9%
Carotid Atherosclerosis
9%
Rheumatic Disease
9%
Agglutinin
9%
Amaranthus caudatus
9%
Methotrexate Polyglutamate
9%
Asthma
9%
Pancreas Adenocarcinoma
9%
Glycan
9%
Inflammatory Arthritis
9%
Scoliosis
9%
Controlled Clinical Trial
9%
Keyphrases
Japan
96%
COVID-19
63%
Confidence Interval
58%
Long COVID
38%
Odds Ratio
30%
Chronic Obstructive Pulmonary Disease
29%
Brain Metastases
29%
Utopia
28%
Type 2 Diabetes Mellitus (T2DM)
28%
Multicenter Cohort Study
26%
Risk Factors
25%
Stereotactic Radiosurgery
24%
Aortic Events
23%
Type 2 Diabetic Patients
22%
Propensity Score Analysis
20%
Body Mass Index
20%
Nationwide Survey
19%
St. George's Respiratory Questionnaire
19%
Tofogliflozin
19%
Congenital Diaphragmatic Hernia
19%
Validation Studies
19%
Graded Prognostic Assessment
19%
Lung Cancer Brain Metastases
19%
Small Cell Lung Cancer
19%
Methotrexate
19%
Asthma
19%
Rheumatoid Arthritis
19%
Type B Aortic Dissection
19%
COVID-19 Outcomes
19%
Smoking Exposure
19%
Hazard Ratio
17%
Uric Acid
15%
Dyspnea
15%
Clinical Characteristics
13%
Retrospective Cohort Study
13%
Elderly Patients
13%
Japanese Patients
12%
Clinical Parameters
12%
Adalimumab
12%
Patient Characteristics
12%
Hemoglobin
11%
Aneurysmal
11%
Age of Onset
11%
Polyneuropathy
11%
Serum Levels
11%
Neonate
11%
Quality of Life
11%
Japanese Population
10%
Long Coronavirus Disease
10%
Infectious Diseases
10%
Psychological Distress
10%
All-cause Mortality
9%
Multivariable
9%
Pack-years
9%
Invasive Mechanical Ventilation
9%
Smart Eye Camera
9%
Clinical Profile
9%
Delayed Onset
9%
History of Cardiovascular Disease
9%
Liver
9%
Training Outcomes
9%
Topiroxostat
9%
Nationwide Epidemiological Survey
9%
SLCO1B1 Polymorphism
9%
COVID-19 Sequelae
9%
Sentinel Node Navigation Surgery
9%
Nontuberculous Mycobacterial Lung Disease
9%
Stump
9%
Anti-VEGF Therapy
9%
FOLFOXIRI
9%
Stage II Colorectal Cancer
9%
Stanford Type B Aortic Dissection
9%
Prospective multi-institutional Study
9%
ABO Blood Group
9%
High-risk Stage II
9%
Endocrinopathy
9%
Organomegaly
9%
Genotype
9%
Chronic Kidney Disease
9%
Nasal Pressure
9%
Baricitinib
9%
Iliac Artery Disease
9%
Left Upper Lobectomy
9%
Olanexidine Gluconate
9%
Lower Respiratory Symptoms
9%
Acetylcholine Receptor Antibody
9%
Matched Cohort Study
9%
Tear Break-up Time
9%
Myasthenia Gravis
9%
Prognostic Significance
9%
Renin-angiotensin System
9%
Skin Changes
9%
Thrombus Formation
9%
Surgical Treatment
9%
Human Subjects
9%
Thalidomide
9%
Pulmonary Vein
9%
Randomized Phase III Trial
9%
Double-blind Randomized Trial
9%
M Protein
9%